MedTrace Logo

Olanzapine for the Prevention of Postoperative Nausea and Vomiting

NCT04718727 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2023-03-09

No results posted yet for this study

Summary

Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for PONV have an estimated 30 to 40% chance of suffering PONV. Olanzapine as an antiemetic represents a new use of an antipsychotic drug.

Conditions

  • Postoperative Nausea

Interventions

DRUG

Placebo

oral Placebo tablets one-hour preoperatively

DRUG

5 mg Olanzapine Tablets

oral 5 mg Olanzapine tablets one-hour preoperatively

DRUG

10 mg Olanzapine Tablets

oral 10 mg Olanzapine tablets one-hour preoperatively

Sponsors & Collaborators

  • Amani Hassan Abdel-Wahab

    lead OTHER

Principal Investigators

  • Amani H Abdel-wahab, MD · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2023-02-01
Completion
2023-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04718727 on ClinicalTrials.gov